Lung cancer after allogeneic hematopoietic stem cell transplantation
Authors:
- Maximilian RostMRMaximilian Rost
- Claudia WehrCWClaudia Wehr
- Miriam Mozaffari JoveinMJMiriam Mozaffari Jovein
- Marcel KemperMKMarcel Kemper
- Annalen BleckmannABAnnalen Bleckmann
- Tobias R. OverbeckTOTobias R. Overbeck
- Andreas BraußABAndreas Brauß
- Friedrich StölzelFSFriedrich Stölzel
- Matthias RitgenMRMatthias Ritgen
- Jochen J. FrietschJFJochen J. Frietsch
- David O’REillyDODavid O’REilly
- Martin P. BarrMBMartin P. Barr
Open Access
- 29 September 2026
- journal article
- Published by Elsevier in Lung Cancer
- Vol. 221
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- The next generation of immunotherapies for lung cancersNature Reviews Clinical Oncology, 2025
- Immune checkpoint inhibitors therapy for solid organ malignancies after allogeneic hematopoietic stem cell transplantation: a retrospective study from the EBMT Transplant Complications Working PartyBone Marrow Transplantation, 2024
- The influence of immune checkpoint blockade on the outcomes of allogeneic hematopoietic stem cell transplantationFrontiers in Immunology, 2024
- Clinical features, pathophysiology, and therapy of poor graft function post–allogeneic stem cell transplantationBlood Advances, 2022
- How much has allogeneic stem cell transplant–related mortality improved since the 1980s? A retrospective analysis from the EBMTBlood Advances, 2020
- The Role of Immune Checkpoints after Cellular TherapyInternational Journal of Molecular Sciences, 2020
- Evaluation of Second Solid Cancers After Hematopoietic Stem Cell Transplantation in European PatientsJAMA Oncology, 2019
- Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic TransplantationTransplantation and Cellular Therapy, 2019
- New Malignancies After Blood or Marrow Stem-Cell Transplantation in Children and Adults: Incidence and Risk FactorsJournal of Clinical Oncology, 2003